SCHEMBL3159098

SCHEMBL3159098

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(S)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
PDE4A P27815 1/20 0.36
TRPA1 O75762 2/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MAPT P10636 1/20 0.35
KDM4E B2RXH2 1/20 0.35
AOC3 Q16853 1/20 0.35
USP2 O75604 1/20 0.34
SLCO1B1 Q9Y6L6 1/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14490198 0.83 LMNA (0.44) TDP1LMNAL3MBTL1SLC6A2SLC6A4
SCHEMBL8075340 0.82 TDP1 (0.48) TDP1LMNAL3MBTL1PDE4ATRPA1
SCHEMBL5873439 0.80 TDP1 (0.50) TDP1LMNAL3MBTL1PDE4ASLC6A2
SCHEMBL27825950 0.80 TDP1 (0.50) TDP1LMNAL3MBTL1PDE4ASLC6A2
SCHEMBL4077892 0.80 TDP1 (0.50) TDP1LMNAL3MBTL1PDE4ASLC6A2
Mannitol SCHEMBL27535805 0.76 TSHR (0.58) TDP1LMNAL3MBTL1PDE4ATRPA1
Alcohol SCHEMBL28032136 0.76 AOC3 (0.46) TDP1LMNAL3MBTL1TRPA1SLC6A2
SCHEMBL550791 0.75 AOC3 (0.48) TDP1LMNAL3MBTL1SLC6A2SLC6A4
SCHEMBL550790 0.75 AOC3 (0.48) TDP1LMNAL3MBTL1SLC6A2SLC6A4
SCHEMBL551822 0.75 AOC3 (0.48) TDP1LMNAL3MBTL1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2036901-B1 C-PHENYL 1-THIOGLUCITOL COMPOUND TAISHO PHARMACEUTICAL CO LTD (JP) 2013-05-01 EP claimed
US-20100069460-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-03-18 US claimed
CN-101611023-A The 1-phenyl 1-thio-D-glucitol derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2009-12-23 CN claimed
EP-2103607-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2009-09-23 EP claimed
EP-2952206-B1 PROPHYLACTIC OR THERAPEUTIC DRUG FOR CONSTIPATION TAISHO PHARMACEUTICAL CO LTD (JP) 2018-10-24 EP disclosed
US-10022389-B2 Prophylactic or therapeutic drug for constipation TAISHO PHARMACEUTICAL CO., LTD. (JP) 2018-07-17 US disclosed
US-20150374735-A1 PROPHYLACTIC OR THERAPEUTIC DRUG FOR CONSTIPATION TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-12-31 US disclosed
EP-2952206-A1 PROPHYLACTIC OR THERAPEUTIC DRUG FOR CONSTIPATION Taisho Pharmaceutical Co., Ltd. (JP) 2015-12-09 EP disclosed
US-20100069460-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-03-18 US disclosed
US-20100069460-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-03-18 US disclosed
JP-2010018611-A PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETES, DIABETES-RELATED DISEASES OR DIABETIC COMPLICATIONS CONTAINING 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE AS EFFECTIVE INGREDIENT TAISHO PHARMACEUTICAL CO LTD 2010-01-28 JP disclosed
CN-101611023-A The 1-phenyl 1-thio-D-glucitol derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2009-12-23 CN disclosed
CN-101611023-A The 1-phenyl 1-thio-D-glucitol derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2009-12-23 CN disclosed
CN-101611023-A The 1-phenyl 1-thio-D-glucitol derivative TAISHO PHARMACEUTICAL CO LTD (JP) 2009-12-23 CN disclosed
EP-2103607-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2009-09-23 EP disclosed
EP-2103607-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2009-09-23 EP disclosed
WO-2008072726-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-06-19 WO disclosed
WO-2008001864-A1 C-PHENYL 1-THIOGLUCITOL COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150374735-A1 PROPHYLACTIC OR THERAPEUTIC DRUG FOR CONSTIPATION SLC5A1, SLC5A2, SLC10A2 TDP1 4114/4885LMNA 3968/4885L3MBTL1 3885/4885
US-10022389-B2 Prophylactic or therapeutic drug for constipation SLC5A1, SLC5A2, SLC10A2 TDP1 4114/4885LMNA 3968/4885L3MBTL1 3885/4885
US-20100069460-A1 1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE SLC5A1, SLC5A2, SLC2A1 TDP1 1126/4885LMNA 4603/4885L3MBTL1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.